SteadyMed Hires Pulmonary Hypertension Veteran to Lead Patient Advocacy and Community Relations
December 07 2016 - 8:30AM
SteadyMed Therapeutics Ltd. (NASDAQ:STDY), a specialty
pharmaceutical company focused on the development of drug product
candidates to treat orphan and high-value diseases with unmet
parenteral delivery needs, today announced that it has hired Carl
Hicks, Jr., in a newly created role of Vice President of PH Patient
Advocacy and Community Relations.
Hicks, a 20-year veteran in the fight against
pulmonary hypertension (PH), is a nationally and internationally
recognized advocate for patients, caregivers, and the PH community.
He joins SteadyMed from the Pulmonary Hypertension Association
(PHA), the world’s leading PH patient advocacy organization, where
he served in a number of roles including Executive Vice President,
Chairman of the Board and Board member since 2000. Carl is very
well known and respected nationally and internationally by many PH
physicians, patients and caregivers for his devotion to helping
this community.
“We are delighted that Carl joins us in this
very important role,” said Jonathan Rigby, President & CEO of
SteadyMed. “His devotion to patients and the broader PH community,
as well as his rich, relevant experience will be invaluable to us
as we prepare to file a New Drug Application (NDA) for Trevyent®,
our lead drug product candidate for the treatment of pulmonary
arterial hypertension, in Q2 in 2017. SteadyMed is committed
to building a strong relationship with this underserved patient
population and meeting their needs in a meaningful and impactful
manner.”
“I am thrilled to join SteadyMed, a company that
prides itself with a strong patient focus,” said Carl Hicks, Vice
President, PH Patient Advocacy and Community Relations. “The loss
of my daughter to PH drives me to be a fierce advocate for this
devastating disease. In this role, I am committed to helping
SteadyMed engage with, and address the needs of these patients who
may one day benefit from Trevyent, if approved, by the Food and
Drug Administration (FDA).”
Mr. Hicks’ addition to the SteadyMed team is
well aligned with the launch of our recent BePHenomenal campaign.
In November, SteadyMed launched a new website, BePhenomenal.com,
that is dedicated to educating and empowering people living with PH
so that they can live their healthiest and most PHenomenal lives.
BePhenomenal.com will offer expert lifestyle information customized
for people within the PH community.
About SteadyMed SteadyMed
Ltd. is a specialty pharmaceutical company focused on the
development of drug products to treat orphan and high value
diseases with unmet parenteral delivery needs. The company's lead
drug product candidate is Trevyent®, a development stage drug
product that combines SteadyMed's PatchPump® technology
with treprostinil, a vasodilatory prostacyclin analogue to treat
pulmonary arterial hypertension (PAH). SteadyMed intends
to commercialize Trevyent in the U.S. and has signed an exclusive
license and supply agreement with Cardiome Pharma
Corp. for the commercialization of Trevyent
in Europe, Canada and the Middle
East. SteadyMed has offices in San Ramon,
California and Rehovot, Israel. For additional
information about SteadyMed please
visit www.steadymed.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, statements about
the company's ability to advance its development-stage product
candidates, including Trevyent. Forward-looking statements reflect
the company's current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause actual results to differ materially.
Risks and uncertainties include, but are not limited to, the risk
that Trevyent does not demonstrate clinical superiority to existing
parenteral treprostinil products, that Trevyent is not approved for
commercialization by the FDA, that Trevyent is not granted
orphan drug exclusivity, and the risk that drug development
involves a lengthy and expensive process with uncertain outcome.
The risks, uncertainties and assumptions referred to above are
discussed in detail in our reports filed with the Securities
and Exchange Commission, including our Quarterly Report on Form
10-Q filed on November 14, 2016. The company does not
undertake to publicly update or revise any forward-looking
statements to reflect events or circumstances that may arise after
the date hereof except as may be required by law.
Contact:
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Apr 2023 to Apr 2024